MoonLake Immunotherapeutics (MLTX)
45.69
-1.07
(-2.29%)
USD |
NASDAQ |
Nov 04, 13:31
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.873B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -3.71% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 5.519 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. |
URL | https://www.moonlaketx.com |
Investor Relations URL | https://ir.moonlaketx.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Nov. 14, 2024 (est.) |
Last Earnings Release | Aug. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. |
URL | https://www.moonlaketx.com |
Investor Relations URL | https://ir.moonlaketx.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Nov. 14, 2024 (est.) |
Last Earnings Release | Aug. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |